Experimental combo aims to outsmart resistant lymphoma

NCT ID NCT06675123

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining two drugs—pacritinib and a BTK inhibitor—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to treatment. Ten adults will receive the combination and be monitored for side effects and tumor response. The goal is to find a new option for this hard-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pacritinib combined with a BTK inhibitor

What this could lead to

If it works, this could point toward a new treatment option for patients with mantle cell lymphoma that has returned or not responded to prior therapy.

What could go wrong

This is a very early, small Phase 1 trial with only 10 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact